- Email:
- doylet@iu.edu
Bio:
Tom Doyle, PhD, is an Assistant Research Professor at the IU Center for Bioethics.
Dr. Doyle received his bachelor’s degree in philosophy from Southern Illinois University-Carbondale, and his PhD in philosophy at Purdue University. Additionally, he completed a fellowship in clinical medical ethics at the Fairbanks Center for Medical Ethics at IU Health.
Teaching
Research:
Research Interests:
- Phenomenology of Health and Illness
- Healthcare Access
- Patient Behavior / Medical Decision-Making
Selected Publications:
Doyle TA, Conboy E. What Are Ethical Merits and Drawbacks of Viewing "Medical Mysteries" as Human Subject Research?. AMA Journal of Ethics. 2025.
Doyle TA, Vershaw SL, Conboy E, Halverson CME. Improving Social Media-Based Support Groups for the Rare Community: Interview Study With Patients and Parents of Children with Rare and Undiagnosed Diseases. JMIR Human Factors. 2024.
Halverson CME, Doyle TA. Patients' strategies for numeric pain assessment: a qualitative interview study of individuals with hypermobile Ehlers-Danlos Syndrome. Disabil Rehabil. 2023.
Additional Publications: PubMed
Funding:
Selected Grants:
Enhancing Biobank Trutworthiness: Designing and Testing a Transparenct Initiative
2025-2026, ($158,131)
With this funding, Dr. Schwartz and Dr. Doyle will develop a web tool for Indiana biobanks to explain to donors how their data and samples are being used in research, building upon their past work on public deliberation in Indiana.
Understanding Access Barriers to Diagnostic Technologies in Underserved Communities
2025-2026, ($158,500)
Dr. Doyle will study healthcare access barriers for Hoosiers with rare and undiagnosed diseases.
Artificial Intelligence-based & Ethically-focused Milti-Modal Data Integration Framework for Screening, Diagnosing, and Caring for Chronic Kidney Disease (CKD) Patients
2025-2027, ($4,090,889)
Dr. Schwartz and Dr. Doyle will meet with patients with chronic kindey disease (CKD) and use Artificial Inteligence to improve potential predictions of the disease as well as conduct online studies to identify ethical issues, and act as guides for developing AI for CKD predictions.